Dewi Latifatul Ilma

Dewi Latifatul Ilma

Auto-generated profile, based on publicly available information

Dewi Latifatul Ilma

Department of Pharmacy, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia, Indonesia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in JPSCR: Journal of Pharmaceutical Science and Clinical Research
Verified
Journal Article
Open access
PDF file
ASAnisa Dwi Sasanti
Anisa Dwi Sasanti
LMLaksmi Maharani
Laksmi Maharani
NSNia Kurnia Sholihat
Nia Kurnia Sholihat
TPTunggul Adi Purwonugroho
Tunggul Adi Purwonugroho
IMIka Mustikaningtias
Ika Mustikaningtias
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
Pandemi coronavirus disease-19 (COVID-19) menyebabkan perubahan pelayanan kesehatan. Upaya mengurangi penyebaran COVID-19 adalah menjaga jarak dan menghindari kerumunan. Pada layanan kesehatan, telefarmasi memberikan akses cepat dan kenyamanan yang baik. Penelitian ini bertujuan mengeksplorasi peran dan perilaku apoteker dalam penggunaan telefarmasi serta faktor-faktor yang mempengaruhi penerapan telefarmasi selama pandemi COVID-19. Penelitian dilakukan menggunakan metode non-eksperimental kualitatif fenomenologis melalui wawancara mendalam. Informan diambil hingga data jenuh dan diperoleh 5 informan. Wawancara dilakukan langsung maupun online. Keabsahan data melalui uji kredibilitas dengan member checking, uji transferabilitas dengan uraian rinci, uji dependabilitas dan uji konfirmabilitas melalui peer debrifing. Hasil wawancara dianalisis secara deskriptif dengan proses berpikir induktif. Peran apoteker dalam telefarmasi selama pandemi COVID-19 adalah memberikan layanan telefarmasi yang profesional, sedangkan perilaku apoteker adalah memanfaatkan telefarmasi untuk memberikan layanan farmasi klinik dan menggunakan media yang bervariasi. Faktor pendukung penerapan telefarmasi selama pandemi adalah kerja sama rekan sejawat dan keluarga pasien, peraturan terkait dukungan telefarmasi, dan pandemi COVID-19; sedangkan faktor penghambatnya adalah teknologi, hambatan finansial pasien, penerimaan pasien terhadap telefarmasi, keterbatasan sumber daya manusia dan waktu.

30 September 2019 in Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)
Verified
Journal Article
Open access
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
DWDjoko Wahyono
Djoko Wahyono
ISIka Puspita Sari
Ika Puspita Sari
Pneumonia is one of the major causes of mortality due to infection in hospitalized patients. It was frequently found in patients with renal failure. Clinical outcomes of infected patients with renal failure are worse compared to patients without renal failure. The presence of renal impairment affects the pharmacokinetics of the drug. Ceftazidime is one of the most commonly used antibiotics in patients with pneumonia. Approximately, 80-90% of ceftazidime’s total drug fraction is eliminated by kidneys so that the presence of kidney disorders will affect the concentration of ceftazidime in the blood. This study aimed to determine the estimated concentration of ceftazidime in the blood and clinical outcome of pneumonia patients with renal impairment. This study was a retrospective study with descriptive observational design. Data were obtained from patient’s medical record in a hospital in Yogyakarta between January 2013-June 2017 which fulfilled the inclusion criteria, i.e., ≥18 years old patients with complete medical record data, treated in internal medicine ward with diagnosis of pneumonia (HAP/HCAP) who had chronic renal failure, and received ceftazidime for minimum 72 hours or 3 days. The number of research samples were 40 patients. This study showed that 31 patients (77.5%) had achieved estimated ceftazidime concentration in the blood above the minimum inhibitory concentration of 8 μg/ mL. After ceftazidime therapy, 19 patients (47.5%) had improved clinical outcome and 21 patients (52.5%) had not improved clinical outcome.

31 March 2022 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
TPTunggul Adi Purwonugroho
Tunggul Adi Purwonugroho
Background: The trend of using nutraceuticals in Indonesia increases every year. This study aims to describe nutraceuticals consumed in pediatrics with epilepsy as additional antiepileptic therapy and analyze their potential drug interactions. Methods: This research was a cross-sectional study with total sampling method which was carried out in the period of June to July 2020. Inclusion criteria were children with epilepsy aged 0-17 years who were members of the Indonesian Epilepsy Community, had a doctor's diagnosis of epilepsy, received oral antiepileptic medication, and took nutraceutical products/food supplements. Data were analyzed descriptively based on data obtained through electronic data filling sheets and interviews. Results: There were 106 participants from the Indonesian Epilepsy Community in total, with 14 children (13.2 %) using nutraceutical supplements. They were male (n=8; 57.1%), 2-12 years old (n=10; 71.4%), and good nutritional status (n=10; 71.4%). Most nutraceuticals consumed were dietary supplements containing vitamins (n=10; 71.4%). Of the eight potential drug interactions identified, 25% (n=2) were significant interactions, and 75% (n=6) were minor interactions. The potential for major interactions occurred in administering nutraceutical products containing vitamin D with the antiepileptic drug phenytoin and phenobarbital. Conclusion: In this study, nutraceuticals and antiepileptic drugs had a little clinically meaningful interaction effect.

2 April 2026 in The Indonesian Journal of Public Health
Verified
Journal Article
Open access
PDF file
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
BNBayu Nugraheni
Bayu Nugraheni
NSNia Kurnia Sholihat
Nia Kurnia Sholihat
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
Introduction: Medication errors are events that can compromise patients’ safety. A total of 19,639 cases were reported in community pharmacies in Toronto between 2018-2021, with pharmacists and patients identifying 7,053 (35.9%) and 6,533 cases (33.3%), respectively. Several studies have shown that improving patient engagement is a key strategy to reduce the frequency and impact of the errors. Aims: This study aims to assess the knowledge, attitude, and practice (KAP) regarding the prevention and management of medication errors among patients. Methods: A cross-sectional study was conducted using self-administered questionnaires distributed to patients at pharmacies in Banyumas Regency, Central Java, Indonesia. Data were then analyzed quantitatively using descriptive and inferential statistics. The Mann-Whitney U test, Kruskal-Wallis test, and Spearman's rank correlation were applied to identify variables that significantly affected knowledge, attitude, and practice. Results: The results showed that among 385 respondents, the average total knowledge score was 86.18%, which was considered a high level of knowledge. More than 90% of respondents agreed or strongly agreed with statements related to the prevention and management of medication errors, while 37.69% actively engaged in such practice. The results also showed that age, gender, occupation, and education were found to influence patients' attitude and practice. In addition, patients with a positive attitude were more likely to engage in practice that prevents and manages medication errors. Conclusions: The knowledge, attitude, and practice survey confirmed that patients’ attitudes significantly affect their practices in preventing and managing medication errors, indicating the need to strengthen patient practices to reduce medication errors and improve patient safety.

1 January 2025 in Acta Pharmaciae Indonesia : Acta Pharm Indo
Verified
Journal Article
Open access
PDF file
APAtika Putri
Atika Putri
DIDewi Latifatul Ilma
Dewi Latifatul Ilma
MSMasita Wulandari Suryoputri
Masita Wulandari Suryoputri
NENialiana Endah Endriastuti
Nialiana Endah Endriastuti
Background: Anticoagulants are essential for stroke prophylaxis in atrial fibrillation but carry significant interaction potential with commonly used medications. Understanding the prevalence and patterns of these interactions is crucial for optimizing therapy. Objective: To assess the incidence and characteristics of potential drug-drug interactions (DDIs) in hospitalized atrial fibrillation patients receiving anticoagulant therapy. Methods: This retrospective, descriptive observational study analyzed medical records of 324 atrial fibrillation patients hospitalized between January 2019 and December 2021 at a regional hospital in Banyumas Regency. Potential DDIs were assessed using Lexicomp, Drugs.com, and Merck Manual databases, and categorized by severity, mechanism, and clinical manifestation. Results: Nearly all patients (98.90%) experienced at least one potential DDI. Of 1,249 identified DDI events, most were moderate in severity (83.27%) and primarily involved warfarin (69.73%). Pharmacodynamic mechanisms predominated (51.24%), and decreased anticoagulant efficacy was the most common potential clinical manifestation (64.21%). Warfarin accounted for most pharmacokinetic (10.49%) and pharmacodynamic (32.42%) interactions. Elderly patients (>65 years) constituted the largest population group (40.74%), and most patients (65.74%) had atrial fibrillation as a secondary diagnosis. Conclusion: The high prevalence of potential DDIs involving anticoagulants in hospitalized atrial fibrillation patients underscores the need for vigilant medication management, particularly for patients receiving warfarin and those with multiple comorbidities.